Instrument Inactif

Autres langues Celltrion, Inc. Korea S.E.

Actions

068270

KR7068270008

Recherche biotechnologique et médicale

Cours en clôture Korea S.E.
- ^KRW	-

25/08	Celltrion lance le dosage à 300 mg d'Omlyclo sur les principaux marchés européens	CI
24/08	Celltrion dépose une demande de commercialisation pour son biosimilaire du Keytruda en Corée du Sud	MT

Autres langues

25/08	Celltrion Launches Omlyclo 300 Mg Strength In Key European Markets
24/08	Celltrion Submits Marketing Application for Keytruda Biosimilar in South Korea
18/08	Celltrion's Acquired French Healthcare Firm Becomes Fully Operational
14/08	Celltrion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Celltrion Files Phase 3 Trial Amendment for CT-P44 Biosimilar for Myeloma
27/07	Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability
24/07	Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55
24/07	Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug
24/07	Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug
14/07	Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar
07/07	Celltrion : Vegzelma completes formulary listings with two major U.S. PBMs, expanding reimbursement access to drive further U.S. growth
07/07	Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA
03/07	South Korean Shares Jump on Bargain-Hunting, Chip Stock Gains
03/07	Celltrion's Sales Jump 35% in Q2; Shares Rise 4%
03/07	Celltrion : Reports Preliminary Q2 2026 Revenue of KRW 1.3Tn and Operating Profit of KRW 430Bn… Achieving Record-High Second-Quarter Performance, Raising Expectations for Full-Year Target Outperformance
03/07	Samsung, SK Hynix Lead KRW 392 Trillion Investment in South Korea's Chungcheong Region
30/06	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 21, 2026.
26/06	Celltrion, Inc.'s Equity Buyback announced on May 21, 2026, has closed with 586,927 shares, representing 0.26% for KRW 99,872.81 million.
19/06	South Korean Shares Snap Six-Day Winning Streak on Profit-Booking
19/06	Celltrion's EU Clinical Trial Nod for Crohn's Disease Drug Lapses
19/06	Celltrion's EU Clinical Trial Nod for Ulcerative Colitis Drug Lapses
02/06	Celltrion Workers Form Labor Union
31/05	Celltrion, Inc. completed the acquisition to acquire Gifrer Barbezat SAS.
21/05	Celltrion, Inc. authorizes a Buyback Plan.
21/05	Celltrion, Inc. announces an Equity Buyback for 557,414 shares.